Bio Tech

C4 Theraputics

Biopharmaceutical company developing a new class of small molecules to direct the machinery of the ubiquitin-proteasome system to degrade disease-relevant proteins for therapeutic benefit.

www.c4therapeutics.com

OncoPep

Bio Pharmaceutical company developing targeted immunotherapeutics to prevert the progression of cancer.

www.oncopep.com

Acetylon

Clinical Stage Bio Pharmaceutical company

SOLD to Celgene Q4 2016

Regenacy

Regenacy Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company developing treatments for peripheral neuropathies, hemoglobinopathies and certain oncology indications based on regeneration of normal protein function with oral, isoform selective histone deacetylase enzyme (“HDAC”) inhibitors.

www.regenacy.com

Frequency Therapeutics

Clinical Stage Bio Pharmaceutical company developing topical treatment to reverse hearing loss through progenitor cell activation therapies. Frequency went public in September 2019.

www.frequencytx.com

Information Technology

Kard

Credit card mileage optimizer

www.getkard.com

MANA       

MANA: T cells targeting multiple tumor antigens are the cornerstone of MANA’s approach to treating Cancer.

ONCOMYX

ONCOMYX Therapeutics is developing oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement.

XFOR.

X4 is developing therapeutics to target the CXCR4 pathway to restore healthy immunity in patients with rare diseases.

XVAX     

X-VAX is committed to developing vaccines against pathogens acquired by mucosal infection such as Herpes.

LIPIDIO  

LIPIDIO is focused on advancing a molecule to treat diseases associated with excess body fat including non-alcoholic steatohepatitis (NASH), Prader-Willi syndrome (PWS) and antipsychotic drug-induced weight gain (AIWG), which represent major unmet medical needs.

VISGENX 

VISGENX is developing therapeutics to protect against the loss of sight from retinal disorders ie. Age Related Dry Macular Degeneration. Our programs are based on increasing the expression of a gene(s) which may prevent the loss of retinal cells critical for vision.

www.visgenx.com/